Protein based tumor necrosis factor-receptor variants for the treatment of TNF related disorders
The invention relates to novel proteins with TNF-receptor antagonist activity and nucleic acids encoding these proteins. The invention further relates to TNF-receptor proteins with reduced immunogenicity and the use of these novel proteins in the treatment of TNF related disorders.
1. An isolated Tumor Necrosis Factor (TNF)-receptor protein comprising an amino acid sequence comprising at least one amino acid substitution as compared to amino acids 15–138 of SEQ ID NO: 1, wherein said amino acid substitution is selected from the group consisting of positions: 65, 66, 67, 69, 72, 75, 77, 78, 79, 80, 105, 107, 108, 111 and 113.
2. An isolated TNF-receptor protein according to claim 1 , wherein said TNF-receptor protein has from 2 to 5 amino acid substitutions as compared to said amino acids 15–138 of SEQ ID NO: 1.
3. A TNF-receptor protein according to claim 1 , wherein said TNF-receptor protein has enhanced antagonistic properties as compared to SEQ ID NO: 1.
4. A TNF-receptor protein according to claims 1 , 2 or 3 wherein said TNF-receptor protein has reduced immunogenicity.
5. A TNF-receptor protein according to claim 1 , wherein said substitution is selected from the group consisting of N65E, N65F, N65V, H66F, H66K, H66R, H66W, L67F, L67K, H69A, H69D, H69E, H69F, H69K, H69R, H69T, H69Y, H69Q, S72A, S72L, S72G, S72N, S72R, S72Q, K75Q, K75R, R77D, R77K, R77L, R77Q, R77V, K78D, K78R, E79A, E79H, E79K, E79S, E79T, E79W, M80A, M80D, M80E, M80L, H105K, W107A, W107B, W107D, W107E, W107F and combinations thereof.
6. A TNF-receptor protein according to claim 5 , wherein said substitutions are selected from the group consisting of: N65F, H66F, H69A, H69D, H69F, H69Y, H69Q, K75R, K78D, M80E, H105K, L67F, S72Q and combinations thereof.
7. A TNF-receptor protein according to claim 6 , wherein said TNF-receptor protein is a double point variant having substitutions selected from the group consisting of H66F and H69A, H66F and H69Y, H66F and H69D, H66F and H69Q, H66F and K75R, K75R and H69A, K75R and H69D, K75R and H69Q, and K75R and H69Y.
8. A TNF-receptor protein according to claim 7 , wherein said double point variant comprises H66F and either H69A or H69D.
9. A TNF-receptor protein according to claim 8 , wherein said double point variant proteins possess reduced immunogenicity.
10. A TNF-receptor protein according to claims 1 , wherein said TNF-receptor protein is PEGylated.
11. A TNF-receptor protein according to claim 1 , wherein the C-terminal leucine of said amino acids 15–138 of SEQ ID NO: 1 is deleted.
12. A TNF-receptor protein according to claims 1 , 2 , or 3 , wherein two or more TNF-receptor variants are covalently linked via disulfide bonds.
13. A TNF-receptor protein according to claims 1 , 2 , or 3 , wherein two or more TNF-receptor variants are covalently linked via chemical cross linking.
14. A TNF-receptor protein according to claims 1 , 2 , or 3 , wherein two or more TNF-receptor variants are covalently linked by a linker peptide.
15. A TNF-receptor protein according to claim 14 , wherein said linker peptide is a sequence of at least one and not more than about 30 amino acid residues.
16. A TNF-receptor protein according to claim 14 , wherein said linker peptide is a sequence of at least 5 and not more than about 20 amino acid residues.
17. A TNF-receptor protein according to claim 16 , wherein said linker peptide is a sequence of at least 10 and not more than about 15 amino acid residues.
18. A TNF-receptor protein according to claims 14 , wherein the linker peptide comprises one or more of the following amino acid residues: Gly, Ser, Ala, or Thr.
19. A pharmaceutical composition comprising a TNF-receptor protein according to claim 1 and a pharmaceutical carrier.